Pangaea Data awarded top tier co-sell partnership status by Microsoft
South San Francisco, USA - Pangaea Data, provider of a novel AI-driven product for characterizing patients by mapping their journeys and disease trajectories in a privacy-preserving and scalable manner, announces that it has been awarded top tier co-sell partnership status by Microsoft, its highest level partner designation. Microsoft has also extended this status by making Pangaea a transactable…
Ubiquigent appoints Dr Hozefa Amijee as Head of Business Development
Dundee, UK - Ubiquigent Limited, a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, announces the appointment of Dr Hozefa Amijee as Head of Business Development (BD).
The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant
New antigens support research into BA.5 variant, currently responsible for over half of global COVID-19 cases.
Ubiquigent obtains exclusive license for UbiSite technology to strengthen its specialist drug discovery services
Dundee, UK - Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitylase (DUB) modulators as new therapeutics for areas of high unmet medical need, has signed an exclusive license with the University of Southern Denmark for its UbiSite® technology.
Ubiquigent appoints Dr Sheelagh Frame, CSO, to its Board of Directors
New Board appointment supports Ubiquigent’s pursuit of novel DUB modulators as new therapeutics to address areas of high unmet medical need
FUJIFILM Irvine Scientific PRIME-XV Stem FreezIS DMSO-Free Cryopreservation Medium to be used in FDA-authorized clinical trial
SANTA ANA, Calif., - FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for bioproduction and cell therapy manufacturing, announces that its PRIME-XV Stem FreezIS DMSO-Free* cryopreservation medium is to be used as an excipient in a FDA-authorized clinical trial conducted by Vitro Biopharma.
Astrea Bioseparations introduces Nereus LentiHERO, a fit-for-purpose solution for lentiviral vector purification
Cambridge, UK - Astrea Bioseparations, a leading provider of novel purification and separation tools supporting the development of next-generation therapeutics, announces the commercial launch of its Nereus LentiHERO™ lentiviral vector (LVV) purification technology.
Yourgene Health Receives HSA approval for IONA Nx NIPT Workflow in Singapore
Manchester, UK - Yourgene Health plc (“Yourgene”, AIM: YGEN), a leading international molecular diagnostics group, announces it has received Health Sciences Authority (HSA) approval for its IONA® Nx NIPT Workflow in Singapore.
H.E.L Group strengthens leadership team to focus on new product development and enhanced customer support
Alan Lockley joins as Director of Global Services, Edward Quinn as Director of Product Development and Mark Appleton takes new role as Director of Research.
Avacta announces AVA6000 receives Orphan Drug Designation from the US Food and Drug Administration
London and Wetherby, UK - Avacta Group plc, a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the company’s lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma.
Global Access Diagnostics acquires manufacturing rights for IT-LEISH rapid diagnostic test from Bio-Rad Laboratories
Bedford, UK - Global Access Diagnostics (GADx), a social enterprise prioritising equitable access to diagnostics and driving local manufacturing, announces it has acquired the manufacturing rights for the IT-LEISH rapid diagnostic test (RDT) for visceral leishmaniasis (VL) from Bio-Rad, a global leader in life science research and clinical diagnostic products.
Avacta announces Phase I clinical study of AVA6000 to advance to the fourth cohort
London and Wetherby, UK - Avacta Group plc, a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the first-in-human Phase I trial (ALS-6000-101) of AVA6000 Pro-doxorubicin will advance to the fourth dose cohort of patients following a positive review of the safety and tolerability data from the…
Bio-Rad introduces anti-evolocumab antibodies for use in preclinical and clinical drug development
HERCULES, Calif. — Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, introduces a range of type 1 antibodies that inhibit the binding of evolocumab (Repatha®) to its target, human proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that has been shown to play a key role in the regulation of cholesterol levels. These sequence…
Bio-Rad extends range of StarBright Violet and UltraViolet Dyes for multiplex flow cytometry
HERCULES, Calif, — Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, extends its range of StarBright Dyes to provide greater flexibility in multicolor flow cytometry panels. The StarBright Violet 760, StarBright UltraViolet 575, and StarBright UltraViolet 605 Dyes offer improved brightness with narrow excitation and emission profiles for…
CrestOptics’ DeepSIM super resolution confocal microscope module named by Microscopy Today as a Top 10 Best Microscopy Innovation of 2022
CrestOptics, a manufacturer of high-end microscopy solutions and advanced systems for fluorescence microscopy and diagnostic applications, has been recognised as developing one of the ten best microscopy innovations in the 2022 Microscopy Today Innovation Awards, DeepSIM.
Closed Loop Medicine appoints David Van Sickle as Non-Executive Director and Simon Ramsden as Chief Financial Officer
London, UK - Closed Loop Medicine Ltd, a leading TechBio company developing combination prescription drug plus software therapy products that enable personalised dose optimisation, announces it has appointed David Van Sickle PhD as Non-Executive Director and Simon Ramsden as Chief Financial Officer.
FUJIFILM Irvine Scientific Launches Heavy Oil for Embryo Culture: Optimized Protection for the IVF Laboratory
SANTA ANA, Calif., FUJIFILM Irvine Scientific, Inc., a world leader in the innovation, development, and manufacture of cell culture media and assisted reproductive technologies (ART), announces the launch of its Heavy Oil for Embryo Culture, a sterile mineral oil with an optimal weight viscosity that provides the ideal balance between ease of use and protection.
CN Bio opens new laboratory facilities to extend Organ-on-a-chip contract research services capabilities
State-of-the-art laboratories significantly expand project capacity to meet increasing market demand for Organ-on-a-Chip research services
FUJIFILM Irvine Scientific Opens New Armstrong R&D Cell Culture Center of Excellence
SANTA ANA, California, FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for bioproduction and cell therapy manufacturing, has announced the completion of its Armstrong Cell Culture Center of Excellence. More than doubling the R&D facility’s footprint, the new state-of-the-art center enables the Company to…
Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Bioanalysis and Drug Monitoring
Hercules, Calif - Bio-Rad Laboratories, Inc, a global leader in life science research and clinical diagnostic products, extends its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of antibodies specific to brentuximab vedotin (Adcetris), secukinumab (Cosentyx), and the secukinumab–interleukin 17A (IL-17A) drug-target complex. These sequence-defined antibodies are…
Centauri Therapeutics strengthens senior leadership team with three key appointments
Centauri Therapeutics Limited (Centauri), an immunotherapy company focused on the treatment of infectious diseases, today announced three senior appointments: Dr Jennifer Schneider as Chief Executive Officer (CEO), Dr Helen Bright as Vice President (VP) of Research & Development (R&D), and Professor David Roblin FRCP FMedSci as Chair of the Board of Directors.
Ubiquigent appoints Professor Helen Walden and Professor John Davis to Scientific Advisory Board
Experts in structural biology and drug development will help exploit the deubiquitylase (DUB) enzyme family as new drug targets
Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss
Mogrify Limited, a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, and Astellas Pharma Inc., a leader in regenerative medicine, today announced that they have executed a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss.
LG Chem renews license triggering payment to Avacta
LG Chem will now proceed with Investigational New Drug (IND) enabling studies for Affimer PD-L1 antagonist programme
Avacta announces second dose escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the first-in-human Phase I trial (ALS-6000-101) of AVA6000 Pro-doxorubicin will advance to the third dose cohort following a positive review of the safety data from the dosing of the second cohort.